Perseus Proteomics Inc
TSE:4882

Watchlist Manager
Perseus Proteomics Inc Logo
Perseus Proteomics Inc
TSE:4882
Watchlist
Price: 570 JPY -3.72% Market Closed
Market Cap: 8.4B JPY
Have any thoughts about
Perseus Proteomics Inc?
Write Note

Perseus Proteomics Inc
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Perseus Proteomics Inc
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
Perseus Proteomics Inc
TSE:4882
PP&E Net
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
PP&E Net
ÂĄ6.5B
CAGR 3-Years
23%
CAGR 5-Years
21%
CAGR 10-Years
30%
PeptiDream Inc
TSE:4587
PP&E Net
ÂĄ17.2B
CAGR 3-Years
39%
CAGR 5-Years
24%
CAGR 10-Years
59%
Takara Bio Inc
TSE:4974
PP&E Net
ÂĄ50.6B
CAGR 3-Years
13%
CAGR 5-Years
16%
CAGR 10-Years
10%
Pharma Foods International Co Ltd
TSE:2929
PP&E Net
ÂĄ4.6B
CAGR 3-Years
-1%
CAGR 5-Years
26%
CAGR 10-Years
21%
C
Cuorips Inc
TSE:4894
PP&E Net
ÂĄ514.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Perseus Proteomics Inc
Glance View

Market Cap
8.4B JPY
Industry
Biotechnology

Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Meguro-Ku, Tokyo-To and currently employs 21 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.

Intrinsic Value
732.02 JPY
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Perseus Proteomics Inc's PP&E Net?
PP&E Net
0 JPY

Based on the financial report for Mar 31, 2024, Perseus Proteomics Inc's PP&E Net amounts to 0 JPY.

Back to Top